Pharmaceutical firms brace for specter of massive drug price cuts

Domestic drug firms are scrambling to slash their administrative and promotional expenses from the current 40 percent to 30 percent, as they are expected to face serious financial losses starting next year with the specter of the specter of the government’s defoaming price plan looming larger and their financial soundness rapidly worsening amid falling revenues by 15 percent on average.

Thus...